Words by Isabel O’Brien
The British Medical Association has responded to an independent review of the NHS, conducted by Lord Darzi, Director of the Institute of Global Health Innovation, Imperial College, which said system is in “critical condition”, grappling with issues that range from surging waiting times and care quality concerns to staff shortages and underfunding.
The review paints a sobering picture, highlighting that “flatlining resource budgets and capital starvation over the past 15 years are a primary cause of the health system’s performance issues”. For the pharmaceutical industry, however, this situation presents an opportunity: to step in as a partner in healthcare innovation and support the NHS at a turbulent time.
One of the most promising developments is the push towards a digital NHS. The government’s plan, as reported by the BMA, is to move “from an analogue to a digital NHS” by “using technology to empower patients and giving them much greater control over their healthcare—with the NHS app acting as the digital front door to the NHS”.
This presents a unique opportunity for pharma companies to invest in digital health platforms, remote monitoring systems and AI-driven diagnostics, to support the NHS’s digital transformation. These tools not only deliver efficiencies but also empower patients to take an active role in managing their health, reducing the burden on an already overstretched system.
Primary care, meanwhile, is under immense pressure, and Lord Darzi’s review stresses the importance of government action, noting that “it is imperative that the new Government fully appreciates the gravity of the situation, trusting doctors and experts to facilitate swift action”.
With primary care acting as a gateway to the rest of the healthcare system, pharma can also provide vital support in this area. By providing digital patient management tools, developing educational initiatives and working directly with practices implement new treatments, they can ensure that patients receive timely care and reducing pressure on hospitals.
Addressing the mental health crisis is another key area where pharma can contribute. “The Darzi review acknowledges the rapid deterioration of the country’s mental health. Funding and staffing levels have not kept up with need,” the BMA states.
As demand for mental health services continues to grow rapidly, pharma companies specialising in psychiatric and neurological care can advocate for better access to treatments and work closely with healthcare providers to ensure that patients have the support they need. By focusing on this underserved area, pharma can help the NHS meet its targets while improving the quality of life for millions of people.
Overall, Lord Darzi’s review, as outlined by the BMA, is a stark reminder of the challenges facing the NHS, but it also presents a roadmap for reform. Now is the time for pharma to step up as a strategic partner and help transform the future of healthcare in the UK. But will companies take the opportunity? Only time will tell.
